Medpace (NASDAQ:MEDP) Releases FY 2025 Earnings Guidance

Medpace (NASDAQ:MEDP) updated its FY 2025 earnings guidance on Monday. The company provided earnings per share (EPS) guidance of 11.930-12.690 for the period, compared to the consensus estimate of 12.940. The company issued revenue guidance of $2.1 billion-$2.2 billion, compared to the consensus revenue estimate of $2.2 billion.

Medpace Trading Up 0.1 %

Shares of NASDAQ MEDP opened at $354.51 on Tuesday. Medpace has a 12-month low of $302.01 and a 12-month high of $459.77. The company has a market cap of $11.02 billion, a price-to-earnings ratio of 31.04, a price-to-earnings-growth ratio of 1.85 and a beta of 1.36. The stock’s 50 day simple moving average is $343.88 and its 200 day simple moving average is $349.52.

Medpace (NASDAQ:MEDP) last posted its earnings results on Monday, February 10th. The company reported $3.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.96 by $0.71. Medpace had a return on equity of 50.87% and a net margin of 17.66%. As a group, equities analysts forecast that Medpace will post 11.93 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms have commented on MEDP. Redburn Atlantic assumed coverage on shares of Medpace in a research report on Monday, October 14th. They issued a “buy” rating and a $404.00 target price for the company. Truist Financial decreased their price objective on Medpace from $415.00 to $397.00 and set a “hold” rating for the company in a report on Monday, October 14th. William Blair reaffirmed an “outperform” rating on shares of Medpace in a research note on Tuesday, October 22nd. TD Cowen decreased their price target on Medpace from $413.00 to $372.00 and set a “buy” rating for the company in a research note on Wednesday, October 23rd. Finally, Robert W. Baird lifted their price objective on shares of Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a research note on Monday, January 27th. Seven equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, Medpace has a consensus rating of “Hold” and an average price target of $381.44.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.